Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$125.67 USD

125.67
4,094,076

+8.36 (7.13%)

Updated May 13, 2024 04:00 PM ET

After-Market: $125.55 -0.12 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

by Sanghamitra Saha

These leveraged ETFs won last week despite a broader market bloodbath.

Tirthankar Chakraborty headshot

5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check

by Tirthankar Chakraborty

A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -

Kinjel Shah headshot

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

by Kinjel Shah

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

Nilanjan Banerjee headshot

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

by Nilanjan Banerjee

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

Ekta Bagri headshot

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

by Ekta Bagri

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Will Moderna Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Moderna

Tirthankar Chakraborty headshot

Top Stock Trades to Beat Coronavirus Blues in April

by Tirthankar Chakraborty

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $30.48, moving +1.43% from the previous trading session.

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

by Zacks Equity Research

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Top Ranked Momentum Stocks to Buy for March 30th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th

Why Is Moderna (MRNA) Up 6.8% Since Last Earnings Report?

by Zacks Equity Research

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

Manaswita Ghosh Dutta headshot

3 Best U.S. Stocks Immune to Coronavirus Jitters

by Manaswita Ghosh Dutta

The pandemic may be taking a toll on markets right now but this temporary phase offers investors a window to buy equities that have a record of performing better than the broader markets.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

Daniel Laboe headshot

How To Play The W-Shaped Recovery

by Daniel Laboe

Patience is the name of the game during market downturns

Novavax Rallies as Influenza Vaccine Meets All Goals in Study

by Zacks Equity Research

Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.

Daniel Laboe headshot

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

by Daniel Laboe

It is only a matter of time before this virus anxiety is a thing of the past.

Coronavirus Drug Development Race to Boost These 4 Stocks

by Zacks Equity Research

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Aytu BioScience to Issue Coronavirus Rapid Test in North America

by Zacks Equity Research

Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine

by Zacks Equity Research

Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.